Research programme: mRNA cancer vaccines - Repertoire Immune Medicines
Latest Information Update: 30 Jan 2025
Price :
$50 *
At a glance
- Originator Repertoire Immune Medicines
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Non-small cell lung cancer
Most Recent Events
- 07 Aug 2024 Early research in Non-small cell lung cancer in USA (Parenteral), prior to August 2024 (Repertoire Immune Medicines pipeline, August 2024)